Peppermint Bloating Meta-Analysis Evidence Table

Structured evidence table for Peppermint Bloating Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Peppermint Bloating Meta-Analysis1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities [].3Šuran Jelena (2026)IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
Peppermint Bloating Meta-AnalysisEarly studies reported SIBO in up to 60–78% of IBS cases based on lactulose breath testing [,,], though later investigations using more rigorous methods found lower prevalences (e.g., 4–20%) [,].3Šuran Jelena (2026)IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
Peppermint Bloating Meta-AnalysisMoreover, increasing evidence implicating the gut microbiota in IBS/SIBO has spurred interest in interventions that modulate microbial communities.3Šuran Jelena (2026)IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
Peppermint Bloating Meta-AnalysisIt affects an estimated 5–10% of the global population and is more common in women, imposing a significant burden on quality of life and healthcare resources [].3Šuran Jelena (2026)IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
Peppermint Bloating Meta-AnalysisWe examine current guideline recommendations, real-world treatment patterns, and evidence supporting both pharmacological and non-pharmacological interventions.4Sacco R (2026)Revisiting Abdominal Pain in IBS: From Pathophysiology to Targeted Management with Alverine Citrate/Simeticone.
Peppermint Bloating Meta-AnalysisAbdominal pain is the cardinal symptom of irritable bowel syndrome (IBS) and the primary determinant of disease burden and healthcare utilization.4Sacco R (2026)Revisiting Abdominal Pain in IBS: From Pathophysiology to Targeted Management with Alverine Citrate/Simeticone.
Peppermint Bloating Meta-AnalysisDespite its diagnostic centrality and high prevalence across all IBS subtypes, effective management remains a clinical challenge.4Sacco R (2026)Revisiting Abdominal Pain in IBS: From Pathophysiology to Targeted Management with Alverine Citrate/Simeticone.
topicPeppermint Bloating Meta-Analysis
claim1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities [].
evidence level3
citationŠuran Jelena (2026)
sourceIBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
topicPeppermint Bloating Meta-Analysis
claimEarly studies reported SIBO in up to 60–78% of IBS cases based on lactulose breath testing [,,], though later investigations using more rigorous methods found lower prevalences (e.g., 4–20%) [,].
evidence level3
citationŠuran Jelena (2026)
sourceIBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
topicPeppermint Bloating Meta-Analysis
claimMoreover, increasing evidence implicating the gut microbiota in IBS/SIBO has spurred interest in interventions that modulate microbial communities.
evidence level3
citationŠuran Jelena (2026)
sourceIBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
topicPeppermint Bloating Meta-Analysis
claimIt affects an estimated 5–10% of the global population and is more common in women, imposing a significant burden on quality of life and healthcare resources [].
evidence level3
citationŠuran Jelena (2026)
sourceIBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
topicPeppermint Bloating Meta-Analysis
claimWe examine current guideline recommendations, real-world treatment patterns, and evidence supporting both pharmacological and non-pharmacological interventions.
evidence level4
citationSacco R (2026)
sourceRevisiting Abdominal Pain in IBS: From Pathophysiology to Targeted Management with Alverine Citrate/Simeticone.
topicPeppermint Bloating Meta-Analysis
claimAbdominal pain is the cardinal symptom of irritable bowel syndrome (IBS) and the primary determinant of disease burden and healthcare utilization.
evidence level4
citationSacco R (2026)
sourceRevisiting Abdominal Pain in IBS: From Pathophysiology to Targeted Management with Alverine Citrate/Simeticone.
topicPeppermint Bloating Meta-Analysis
claimDespite its diagnostic centrality and high prevalence across all IBS subtypes, effective management remains a clinical challenge.
evidence level4
citationSacco R (2026)
sourceRevisiting Abdominal Pain in IBS: From Pathophysiology to Targeted Management with Alverine Citrate/Simeticone.

Source documents

  1. IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions
  2. Revisiting Abdominal Pain in IBS: From Pathophysiology to Targeted Management with Alverine Citrate/Simeticone.